These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38104575)

  • 1. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    JAMA Psychiatry; 2024 Aug; 81(8):749-756. PubMed ID: 38691387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
    Correll CU; Angelov AS; Miller AC; Weiden PJ; Brannan SK
    Schizophrenia (Heidelb); 2022 Dec; 8(1):109. PubMed ID: 36463237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
    Weiden PJ; Breier A; Kavanagh S; Miller AC; Brannan SK; Paul SM
    J Clin Psychiatry; 2022 May; 83(3):. PubMed ID: 35552528
    [No Abstract]   [Full Text] [Related]  

  • 7. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
    Leber A; Ramachandra R; Ceban F; Kwan ATH; Rhee TG; Wu J; Cao B; Jawad MY; Teopiz KM; Ho R; Le GH; Ramachandra D; McIntyre RS
    Expert Opin Pharmacother; 2024 Mar; 25(4):467-476. PubMed ID: 38515004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
    Sauder C; Allen LA; Baker E; Miller AC; Paul SM; Brannan SK
    Transl Psychiatry; 2022 Nov; 12(1):491. PubMed ID: 36414626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
    Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
    Bugarski-Kirola D; Arango C; Fava M; Nasrallah H; Liu IY; Abbs B; Stankovic S
    Lancet Psychiatry; 2022 Jan; 9(1):46-58. PubMed ID: 34861170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial.
    Targum SD; Murphy C; Breier A; Brannan SK
    J Psychiatr Res; 2021 Dec; 144():241-246. PubMed ID: 34700212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial.
    Tassorelli C; Nagy K; Pozo-Rosich P; Lanteri-Minet M; Sacco S; Nežádal T; Guo H; De Abreu Ferreira R; Forero G; Trugman JM
    Lancet Neurol; 2024 Apr; 23(4):382-392. PubMed ID: 38364831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
    Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
    Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.